Alexion Pharmaceuticals Inc. (ALXN) Releases FY13 Earnings Guidance
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) issued an update on its FY13 earnings guidance on Thursday morning. The company provided earnings per share guidance of $3.02-3.04 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.01, ARN reports. The company issued revenue guidance of $1.535-1.540 billion, compared to the consensus revenue estimate of $1.53 billion.
Shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) opened at 109.66 on Thursday. Alexion Pharmaceuticals Inc. has a one year low of $81.82 and a one year high of $125.65. The stock has a 50-day moving average of $111.0 and a 200-day moving average of $100.2. The company has a market cap of $21.445 billion and a price-to-earnings ratio of 62.52.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, October 24th. The company reported $0.83 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.79 by $0.04. The company had revenue of $400.40 million for the quarter, compared to the consensus estimate of $395.10 million. During the same quarter last year, the company posted $0.60 earnings per share. Alexion Pharmaceuticals’s revenue was up 36.1% compared to the same quarter last year. Analysts expect that Alexion Pharmaceuticals Inc. will post $3.03 EPS for the current fiscal year.
Several analysts have recently commented on the stock. Analysts at Zacks upgraded shares of Alexion Pharmaceuticals from a neutral rating to an outperform rating in a research note to investors on Friday, October 18th. They now have a $133.00 price target on the stock. On a related note, analysts at Goldman Sachs Group Inc. raised their price target on shares of Alexion Pharmaceuticals from $122.00 to $139.00 in a research note to investors on Wednesday, September 18th. They now have a hold rating on the stock. One investment analyst has rated the stock with a sell rating, six have given a hold rating and ten have issued a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus price target of $117.40.
Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.